Clinical Trials Browser

Phase 2 × Has results × Diarrhea × Clear all

Diarrhea, Multiple Myeloma

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT00748215 2020-12-02

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

Phase 2 Completed

100 enrolled 17 charts

Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Phase 2 Terminated

62 enrolled 25 charts

Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Phase 2 Terminated

2 enrolled 4 charts

EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Clinical Trials

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome